USE OF STEM CELL IN LIVER

DISEASES
 Liver Diseases

Cirrhosis is currently the 11th most common cause of death globally and
liver cancer is the 16th leading cause of death; in combined they account for
3.5% of all deaths worldwide.
Liver Cirrhosis
Liver Transplantation

Although this liver

cirrhosis is treatable by
liver transplantation, but
the shortage of matching
donors and the high risk
of surgical-associated
complications, further
limits the therapeutic
potential effect of
transplantation.
 Alternative of Liver
Transplantation
Scientists have devised a method to generate large numbers of pure healthy liver
cells from stem cells by the stem cell-based therapy, as an alternative of liver
transplantation and it has attracted interest due to promising results from preclinical
and clinical studies.
What are the benefits of Stem Cells?

 They are non-toxic and devoid of side

effects compared to its toxic drug counterparts.
 Their use for therapeutic purposes can ensure lower
treatment costs and promote longer lives.
 Stem cell therapy addresses both better treatment
giving longer life, and lower costs.
The ability to generate large quantities of stem-cell derived liver cells
holds the potential to sustain patients with liver failure while they await
for a full liver transplant.
 Different Stem Cell Therapy

 Bone Marrow-Derived Mononuclear Cells (BM-

MNCs) in Autologous Liver Cirrhosis Therapy
 Bone Marrow-Derived Hematopoietic Stem Cells
(BM-HSCs) in Autologous Liver Cirrhosis
Therapy
 Bone Marrow-Derived Mesenchymal Stem Cells
(BM-MSCs) in Autologous Liver Cirrhosis
Therapy
 Allogeneic Stem Cells in Liver Cirrhosis Therapy
BM-MNCs in Autologous Liver Cirrhosis Therapy

 1 in 1 × 104 cells and 1 in 5 × 104 cells collectively

known as Mononuclear Cells (MNCs)
 Safer and have great therapeutic potential
 Parkinson
 Myocardial infarction
 Acute renal failure,
 Knee and spinal cord injuries
 BM-HSCs in Autologous Liver Cirrhosis
Therapy
 HSCs have the plasticity to differentiate into non-
hematopoietic lineage cells
 endothelial cells, fibroblasts, myocytes, nephrons and hepatocytes 
 Specific bone marrow-derived stem cells, particularly
CD34+, CD45+ and CD133+ HSCs obtained from the
peripheral blood
 peripheral BM-HSCs can be achieved by either purification of
aspirated BM or the mobilization of HSCs using Granulocyte
Colony Stimulating Factor (G-CSF)
 Dose range of between 1 × 106 to 2 × 108 cells in liver
cirrhosis patients
 either through the portal vein, peripheral vein, or hepatic artery
BM-MSCs in Autologous Liver Cirrhosis Therapy

 Differentiate into a broad range of mesodermal

lineages & embryonic lineages
 The most potent and preferred therapeutic tool
 self-renewing capacity, homing and migration ability,
immunosuppressive potential, and paracrine effects
such as anti-inflammation, anti-apoptosis, anti-
fibrosis/anti-scarring and angiogenesis
Allogeneic Stem Cells in Liver Cirrhosis Therapy

 Limitation is the ability to harvest sufficient numbers of

potent stem cells, especially from elderly patients
 Diseases that deplete their stem cell niches
  Allogeneic MSCs –
 immunosuppressive and immunosurveillance
 evade graft-versus-host rejection due to their unique
 can be isolated from umbilical cord or cord blood, placenta and
amniotic fluid
Stem Cell Transplantation
Most Effective Dose and Route of Administration